Open
育世博生物科技股份有限公司(Acepodia)專注研發新世代癌症細胞免疫療法。育世博應用其特有ACC (Antibody-Cell Conjugation)技術平台，即「抗體-細胞連結技術」，無需基因工程，使用化學連結技術，展現高腫瘤專一、多靶點選擇、低製造成本且安全的特性，發展一系列應用抗體連結免疫細胞(Antibody-Conjugated Effector cells, ACE)，啟動人體免疫機制，導引清除癌症細胞之創新治療方案。育世博期望針對多種目前欠缺有效治療方案的實體與血液腫瘤，開發現成型(Off-the-shelf)細胞治療新藥，陸續有多項產品進入臨床試驗，其HER2表現陽性腫瘤治療新藥ACE1702已進入人體臨床一期試驗，於美國多個癌症中心展開收案。其ACE1831為CD20表現陽性血液腫瘤治療新藥，預計於2021年下半年向美國FDA申請進入人體臨床試驗。
Acepodia is a clinical stage biotech company dedicated to the development of targeted, allogeneic, off-the-shelf cell therapies to eradicate cancers.
Antibody-Cell Conjugation (ACC) platform, its novel technology links tumor-targeting antibodies to the surface proteins of its proprietary immune cells, oNK and γδ T cells. No complicated genetic engineering is required; therefore, the conjugation technology could be powerful, versatile, affordable and safe. The Antibody-Conjugated Effector (ACE) cells significantly increases the avidity with cancer cells, which activates immune system and leads to effectively identifying and eliminating the targeted cancer cells robustly.
Acepodia is a clinical stage biotech company dedicated to the development of targeted, allogeneic, off-the-shelf cell therapies to eradicate cancers.
Antibody-Cell Conjugation (ACC) platform, its novel technology links tumor-targeting antibodies to the surface proteins of its proprietary immune cells, oNK and γδ T cells. No complicated genetic engineering is required; therefore, the conjugation technology could be powerful, versatile, affordable and safe. The Antibody-Conjugated Effector (ACE) cells significantly increases the avidity with cancer cells, which activates immune system and leads to effectively identifying and eliminating the targeted cancer cells robustly.